NRx Pharmaceuticals’ (NRXP) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report released on Monday morning,Benzinga reports. D. Boral Capital currently has a $31.00 price target on the stock.

A number of other analysts have also weighed in on NRXP. HC Wainwright reissued a “buy” rating and issued a $19.00 price target on shares of NRx Pharmaceuticals in a report on Friday, March 14th. Ascendiant Capital Markets lifted their target price on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, December 2nd.

NRx Pharmaceuticals Trading Down 0.9 %

NASDAQ NRXP opened at $2.18 on Monday. The firm has a market cap of $36.88 million, a price-to-earnings ratio of -1.02 and a beta of 1.22. The company has a 50 day moving average of $2.91 and a 200-day moving average of $2.03. NRx Pharmaceuticals has a 1-year low of $1.10 and a 1-year high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Friday, March 14th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.10). On average, analysts forecast that NRx Pharmaceuticals will post -1.75 earnings per share for the current year.

Hedge Funds Weigh In On NRx Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in NRXP. Townsquare Capital LLC bought a new position in shares of NRx Pharmaceuticals during the third quarter worth $25,000. Anson Funds Management LP bought a new position in shares of NRx Pharmaceuticals during the third quarter worth $241,000. Sassicaia Capital Advisers LLC bought a new position in shares of NRx Pharmaceuticals during the fourth quarter worth $33,000. AdvisorShares Investments LLC boosted its position in shares of NRx Pharmaceuticals by 138.5% during the fourth quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock worth $683,000 after purchasing an additional 180,229 shares in the last quarter. Finally, Millennium Management LLC bought a new position in shares of NRx Pharmaceuticals during the fourth quarter worth $61,000. 4.27% of the stock is owned by institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.